A Pharmacodynamic Study of Pre-prostatectomy BKM120 in Men With High-risk, Localized Prostate Cancer
Latest Information Update: 07 Nov 2021
Price :
$35 *
At a glance
- Drugs Buparlisib (Primary)
- Indications Prostate cancer
- Focus Biomarker; Pharmacodynamics
- Sponsors Novartis
- 07 Jan 2021 Status changed from completed to discontinued.
- 07 May 2018 Status changed from active, no longer recruiting to completed.
- 17 Jul 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.